Loading...

Gilead Sciences, Inc.

GIS.DEXETRA
HealthcareDrug Manufacturers - General
97.90
-0.06(-0.06%)

Gilead Sciences, Inc. GIS.DE Peers

See (GIS.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GIS.DE€97.90-0.06%121.8B23.53€4.16+2.71%
LLY.DE€674.40+0.73%639.2B62.91€10.72+0.68%
JNJ.DE€135.84+1.15%326.8B17.30€7.85+3.04%
4AB.DE€167.20+1.46%295.3B81.56€2.05+3.17%
ZEG.DE€127.95+0.63%198.4B29.41€4.35+2.14%
6MK.DE€69.50+1.76%174.5B11.51€6.04+3.83%
AMG.DE€255.15+0.22%137.2B26.58€9.60+3.32%
PFE.DE€20.62+0.98%117.2B17.04€1.21+6.87%
PFE.F€20.59+1.58%117.1B17.16€1.20+6.88%
SNW.DE€88.43+1.09%107.7B17.72€4.99+4.43%
Showing 1 to 10 of 15 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GIS.DE vs LLY.DE Comparison

GIS.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GIS.DE stands at 121.8B. In comparison, LLY.DE has a market cap of 639.2B. Regarding current trading prices, GIS.DE is priced at €97.90, while LLY.DE trades at €674.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GIS.DE currently has a P/E ratio of 23.53, whereas LLY.DE's P/E ratio is 62.91. In terms of profitability, GIS.DE's ROE is +0.25%, compared to LLY.DE's ROE of +0.77%. Regarding short-term risk, GIS.DE is more volatile compared to LLY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for GIS.DE.

Stock Price Comparison

Loading...

Frequently Asked Questions